In a research note, the investment house said that Caliper may be limited in its ability to exceed heightened expectations.
The company's stock took a hit after the investment firm downgraded it to "underweight" from "neutral."
R.W. Baird, the Cowen Group, Jefferies, and UBS each recommended Complete Genomics' stock with target share prices significantly above the company's current trading price.
The investment firm noted the "enormous" market opportunity for Exact Sciences' Cologuard test and predicted it would receive FDA clearance in 2013.
All of the banks issued favorable recommendations on the molecular diagnostics firm's stock.
The bank also placed a price target of $52 on Illumina's stock.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.